JAGX - חוב כולל להון Jaguar Health Corp

The visualized price action confirms the financial standing of Jaguar Health, Inc. (JAGX), whose business relies on plant-based therapy for gastrointestinal disorders and the integration of Mytesi into oncology and HIV treatment. Patent protection and FDA approval create barriers for competitors, although marketing expenses are weighing on capital. Meanwhile, an extensive warehouse network guarantees uninterrupted drug supplies, ensuring high margins. The indicator stands at 2.89.

This ratio compares total liabilities to net assets, determining the degree of financial leverage and the business's dependence on external borrowings. For Jaguar Health, Inc. (JAGX), which is protected by FDA patents for crofelomer, this balance is critical when scaling its monopoly niche. By analyzing the debt-to-equity trend, an investor can assess the risk of equity dilution or the stability of the financing structure in the face of market volatility.